Psychedelic-assisted therapy may be optimized by integrating psychotherapy with the administration of psychoplastogens—substances that promote neuroplasticity. The authors argue that the therapeutic context and psychological support are essential for translating neurobiological changes into lasting mental health improvements. They suggest that without structured psychotherapy, the neuroplastic effects of psychedelics alone are insufficient for sustained clinical benefit. The paper emphasizes the need for careful treatment design that combines pharmacological and psychotherapeutic interventions to maximize outcomes.
A nationwide survey of 918 people with alcohol or substance use disorders found that most support medical research on MDMA (68.1%), believe MDMA-assisted therapy could be useful (70.1%), and would be willing to try it if appropriate (58.8%). Support for research and belief in effectiveness did not differ by race or ethnicity, but small disparities appeared in willingness to try MDMA-assisted therapy and concerns about its use. The findings highlight the need for equitable access and diverse participation as psychedelic-assisted therapy develops.